Showing 990 – 1000 of 1159 results
-
Telix Pharmaceuticals Limited
William Blair initiated research coverage of Telix Pharmaceuticals Limited (TLX-ASX AUD 19.22), a commercial-stage radiopharmaceuticals company that markets Illuccix for imaging prostate cancer and may, pending regulatory approval, also market imaging agents for renal masses and glioblastoma.
-
Insperity, Inc. Initiation
William Blair initiated research coverage of Insperity, Inc. (NSP $93.00), which provides comprehensive PEO and HR outsourcing services to small and midsize businesses.
-
Talkspace, Inc Initiation
William Blair initiated research coverage of Talkspace, Inc. (TALK $5.81), one of the largest pure-play providers of virtual behavioral healthcare in the United States.
-
Xometry Inc Initiation
William Blair initiated research coverage of Xometry, Inc. (XMTR $75.29). Xometry is a leading marketplace for on-demand manufacturing, connecting customers with manufacturing partners that offer a wide range of services, including CNC machining, 3D printing, injection molding, and sheet metal fabrication.
-
DoubleVerify Holdings Inc Initiation
William Blair initiated research coverage of DoubleVerify Holdings, Inc. (DV $29.71), a leading software provider of digital ad measurement and analytics.
-
Latham Group Inc Initiation
William Blair initiated research coverage of Latham Group, Inc. (SWIM $32.70), the leading manufacturer of residential in-ground pools in North America. It also sells pool components and accessories in North America, Australia, and New Zealand.
-
thredUP Inc Initiation
William Blair initiated research coverage of thredUP, Inc. (TDUP $14.98). ThredUP facilitates the sale of secondhand apparel and accessories through its digital marketplace and resale-as-a-service partnerships using its proprietary single-SKU supply chain network to enable sellers to reach a broader group of buyers.
-
Ikena Oncology Inc Initiation
William Blair initiated research coverage of Ikena Oncology, Inc. (IKNA $17.99). Based in Boston, Ikena is developing a pipeline of targeted oncology therapies for novel disease targets, including IK-930, a Hippo pathway inhibitor, which is potentially relevant in up to 10% of all cancers.
-
Alignment Healthcare Inc Initiation
William Blair initiated research coverage of Alignment Healthcare, Inc. (ALHC $26.06), an emerging, technology-enabled Medicare Advantage (MA) plan operator. The company’s mission is to leverage a robust and proprietary IT platform to promote more-efficient, highly coordinated, and lower-cost care for seniors, with the mission of improving healthcare, “one senior at a time.”
-
Praxis Precision Medicines Inc Initiation
William Blair initiated research coverage of Praxis Precision Medicines, Inc. (PRAX $30.04), a clinical-stage biopharmaceutical company translating genetic insights into novel therapies for the treatment of central nervous system disorders.